Cellectar Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. 

CEO
James V. Caruso
CEOJames V. Caruso
Employees
11
Employees11
Headquarters
Florham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded
1996
Founded1996
Employees
11
Employees11

CLRB Key Statistics

Market cap
8.61M
Market cap8.61M
Price-Earnings ratio
-0.21
Price-Earnings ratio-0.21
Dividend yield
Dividend yield
Average volume
255.20K
Average volume255.20K
High today
$5.24
High today$5.24
Low today
$4.61
Low today$4.61
Open price
$5.17
Open price$5.17
Volume
238.50K
Volume238.50K
52 Week high
$94.50
52 Week high$94.50
52 Week low
$4.36
52 Week low$4.36

People also own

Based on the portfolios of people who own CLRB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.